M&As this week: Guanhao Biotech, Sanofi, Grifols Shared Services North America

2 February 2018 (Last Updated February 2nd, 2018 10:00)

Chinese biotechnology company Guanhao Biotech has agreed to purchase a 70% stake in Beihao Stem Cell and Regenerative Medicine Research Institute for CNY63.7m ($10.06m).

Chinese biotechnology company Guanhao Biotech has agreed to purchase a 70% stake in Beihao Stem Cell and Regenerative Medicine Research Institute for CNY63.7m ($10.06m).

Guanhao Biotech will have complete ownership of the regenerative medicine research institute upon completion of the acquisition.

The company has simultaneously agreed to acquire a 50% stake in Beijing Hongguan Regenerative Medical Technology.

Sanofi has agreed to purchase the entire outstanding ordinary shares of Ablynx for €3.9bn ($4.85bn).

The acquisition will strengthen Sanofi’s research and development portfolio and expand its rare blood disorders franchise.

Sanofi is a Belgium-based pharmaceutical company, while Ablynx is a biopharmaceutical company also based in Belgium.

“Sanofi has agreed to purchase the entire outstanding ordinary shares of Ablynx for €3.9bn ($4.85bn).”

Grifols Shared Services North America, a subsidiary of Grifols, has purchased a 51% equity stake in Goetech for $98m.

The acquirer company is a US-based manufacturer of plasma derivative biopharmaceutical products, while the target company, also based in the US, is a technology company involved in the development and commercialisation of mobile and web-based software applications for hospital pharmacies.

Otsuka Pharmaceutical Factory (OPF) has agreed to purchase a 50% stake in Diatranz Otsuka Ltd (DOL) from Australian biotechnology company Living Cell Technologies (LCT) for $3m.

Based in Japan, the acquirer company is a parenteral and enteral nutrition products provider, while the target company, based in New Zealand, is involved in the clinical development, manufacturing and commercialisation of Diabecell.

LCT and DOL have simultaneously signed an agreement for the exclusive licensing of Diabecell in Australia, Argentina and New Zealand, upon FDA approval.